131 related articles for article (PubMed ID: 10614528)
1. Ras mutations are uncommon in sporadic thyroid cancer in children and young adults.
Fenton C; Anderson J; Lukes Y; Dinauer CA; Tuttle RM; Francis GL
J Endocrinol Invest; 1999 Nov; 22(10):781-9. PubMed ID: 10614528
[TBL] [Abstract][Full Text] [Related]
2. Ras oncogene mutations in benign and malignant thyroid neoplasms.
Karga H; Lee JK; Vickery AL; Thor A; Gaz RD; Jameson JL
J Clin Endocrinol Metab; 1991 Oct; 73(4):832-6. PubMed ID: 1890154
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
Cyniak-Magierska A; Brzeziańska E; Januszkiewicz-Caulier J; Jarzab B; Lewiński A
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):594-9. PubMed ID: 17943694
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
6. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.
Goutas N; Vlachodimitropoulos D; Bouka M; Lazaris AC; Nasioulas G; Gazouli M
Anticancer Res; 2008; 28(1A):305-8. PubMed ID: 18383861
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial DNA mutations in differentiated thyroid cancer with respect to the age factor.
Witte J; Lehmann S; Wulfert M; Yang Q; Röher HD
World J Surg; 2007 Jan; 31(1):51-9. PubMed ID: 17171498
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
9. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma.
Hara H; Fulton N; Yashiro T; Ito K; DeGroot LJ; Kaplan EL
Surgery; 1994 Dec; 116(6):1010-6. PubMed ID: 7985080
[TBL] [Abstract][Full Text] [Related]
10. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.
Liu RT; Hou CY; You HL; Huang CC; Hock-Liew ; Chou FF; Wang PW; Cheng JT
Thyroid; 2004 Aug; 14(8):616-21. PubMed ID: 15320975
[TBL] [Abstract][Full Text] [Related]
11. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.
Namba H; Rubin SA; Fagin JA
Mol Endocrinol; 1990 Oct; 4(10):1474-9. PubMed ID: 2283998
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of activating ras mutations in morphologically characterized thyroid nodules.
Ezzat S; Zheng L; Kolenda J; Safarian A; Freeman JL; Asa SL
Thyroid; 1996 Oct; 6(5):409-16. PubMed ID: 8936664
[TBL] [Abstract][Full Text] [Related]
13. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G
J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056
[TBL] [Abstract][Full Text] [Related]
14. Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation.
Wright PA; Williams ED; Lemoine NR; Wynford-Thomas D
Oncogene; 1991 Mar; 6(3):471-3. PubMed ID: 2011403
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Ras mutations in thyroid neoplasia.
Esapa CT; Johnson SJ; Kendall-Taylor P; Lennard TW; Harris PE
Clin Endocrinol (Oxf); 1999 Apr; 50(4):529-35. PubMed ID: 10468914
[TBL] [Abstract][Full Text] [Related]
16. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
17. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.
Basolo F; Pisaturo F; Pollina LE; Fontanini G; Elisei R; Molinaro E; Iacconi P; Miccoli P; Pacini F
Thyroid; 2000 Jan; 10(1):19-23. PubMed ID: 10691309
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
19. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.
Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y
Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231
[TBL] [Abstract][Full Text] [Related]
20. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.
Castro P; Rebocho AP; Soares RJ; Magalhães J; Roque L; Trovisco V; Vieira de Castro I; Cardoso-de-Oliveira M; Fonseca E; Soares P; Sobrinho-Simões M
J Clin Endocrinol Metab; 2006 Jan; 91(1):213-20. PubMed ID: 16219715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]